Kinase Profiling Inhibitor Database

Inhibitor Structure Image Brutto MW Target Reference Reference 2
A-443654 C24H23ON5x2HCl 470.39 Akt1 Shi Y. (2005) Neoplasia 7 992-1000.
A-769662 C20H12N2O3S 360.39 AMPK Activator Cool B. (2006) Cell Metabolism 3 403-416
Amgen TBK 1 inhibitor (Compound II) C28H35N7O4 533.62 TBK1 Ou Y.H. (2011) Molecular Cell 41 458-470
Amgen-NIK-28 C20H20N4O 332.4 NIK Li K. (2013) Bioorganic and Medicinal Chemistry Letters 23 1238-1244
ARA014418 C12H12N4O4S 308.3 GSK3 Noble W. (2005) Proc. Natl. Acad. Sci. USA 102 6990 Bhat R. (2003) J. Biol. Chem. 278 45937
AS601245 (JNK Inhibitor V) C20H16N6S 372.5 JNK Gaillard P. (2005) J. Med. Chem. 48 4596 Carboni S. (2005) J. Neurochem. 92 1054
AX 20017 C13H16N2O2S 264.34 PknG Walburger A (2004) Science 304 1800-1804
Bay 65-1942 C22H26ClN3O4 431.91 IKKb Ziegelbauer K. (2005) British Journal of Pharmacology 145 178-192 (compound A) Moss N.C. (2007) Am J Physiol Heart Circ Physiol 293 H2248-53
BI 2536 C28H39N7O3 521.65 PLK1 Steegmaier M. (2007) Current Biology 17 316-322
BI-78D3 C13H9N5O5S2 379.37 JNK Stebbins J.L. (2008) PNAS 105 16809-16813
BI-D-1870 C19H23N5O2F2 391.42 RSK Sapkota G.P. (2007) Biochem. J. 401 29–38
BI605906 (BIX02514) C17H22F2N4O3S2 432.51 IKKβ Clark K. (2011) Biochem. J. 434 93-104
BIRB-0796 (Doramapimod) C31H37N5O3 527.66 p38 MAPK Regan J. (2002) J. Med. Chem 45 2994-3008
BML-258 (SK1-I) C17H28ClNO2 313.86 SphK1 Paugh S.W. (2008) Blood 112 1382-1391
BMS345541 (IKK Inhibitor III) C14H17N5 255.32 IKBKB Du Z. (2012) J Interferon Cytokine Res. 368-77
BX-320 C23H31BrN8O3 547.45 PDK1 Feldman R.I. (2005) Journal of Biological Chemistry 280 19867-19874
BX-517 C15H14N4O2 282.3 PDK1 Islam I. (2007) Bioorganic and Medicinal Chemistry Letters 17 3814-3818
BX-517 Analog (compound 7b) C19H15N5O2 345.35 PDK1 Islam I. (2007) Bioorganic and Medicinal Chemistry Letters 17 3819-3825
BX-795 C23H26IN7O2S 591.47 PDK1 Feldman R.I. (2005) Journal of Biological Chemistry 280 19867-19874
CGP-57380 C11H9FN6 244.23 MNK Knauf U. (2001) Mol. Cell. Biol. 21 5500-5511 Proud C.G. (2005) Immunity 23 177-189
CGP-57380 analog (SHN-093) C12H11FN6 258.25 MNK Proud C.G. (2005) Immunity 23 177-189
CGP-57380 analog (SHN-095) C13H14N6 254.29 MNK
CHIR 99021 (CT 99021) C22H18Cl2N8 465.34 GSK3 Ring D.B. (2003) Diabetes 52 588
Cot-Tpl2 Inhibitor Compound 10b (Abbott) C20H15N3OS 345.42 Cot-Tpl2 Cusack K. (2009) Bioorganic and MedicinalChemistry Letters 19 1722-1725
Cot-Tpl2 Inhibitor Compound 38 (Abbott) C21H12F3N5OS 439.41 Cot-Tpl2 George D. Friedman M. (2008) Bioorganic and Medicinal Chemistry Letters 18 4952-4955
Cot-Tpl2 Inhibitor Compound 41 (Abbott) C21H14N6O2S 414.44 Cot-Tpl2 George D. Friedman M. (2008) Bioorganic and Medicinal Chemistry Letters 18 4952-4955
CZC-25146 C22H25FN6O4S 488.54 LRRK2 Ramsden N. (2011) ASC Chemical Biology
D 4476 C23H18N4O3 398.41 CK1 Liverton N.J. (1999) J. Med. Chem 42 2180-2190
ETP 46464 C30H22N4O2 470.52 ATRi Toledo L.I. (2011) Nature structural and molecular biology 18 721-727
Febuxostat (TMX-67, Adenuric, Uloric) C16H16N2O3S 316.37 Xanthine oxidase (XO) Gaffo AL. (2010 ) Core Evid. 4 25-36 Grabowski B (2010) Br J Clin Pharmacol. 70 57-64
GDC-0941 C23H29N7O3S2Cl2 586.57 PI3K Folkes AJ. (2008) J Med Chem. 5522-32
GSK2578215A C24H18FN3O2 399.42 LRRK2 Reith A. (2012) Bioorg. Med. Chem. Lett.
GSK650394A C25H22N2O2 382.45 SGK Sherk A. B. (2008) Cancer Res 68 7475–7483
GW843682X (GSK-PLK1 Compound 2) C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021
HG-9-91-01 C32H38ClN7O3 604.14 SIK Clark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91
IKK-2 Inhibitor IV (TPCA-1) C12H10FN3O2S 279.3 IKK2 Podolin P.L. (2005) J. Pharmacol. Exp. Ther. 312 373 Karin M. (2004) Nat. Rev. Drug Discov. 3 17
IPA-3 C20H14O2S2 350.45 PAK1 Deacon S.W. (2008) Chemistry and Biology 15 322
IRAK-4 kinase inhibitor a C22H24N4O6 440.45 IRAK4 Wang Z. (2006) Structure 14 1835-1844
IRAK-4 kinase inhibitor b C22H24N4O6 440.45 IRAK4
Ischemin C15H17N3O4S 335.38 p53 CBP Jagat C. Borah (2011) Chemistry & Biology, 18 4 531-541
JNKIN7 C28H27N7O2 493.56 JNK Zhang T. (2012) Chem Biol. 19(1) 140-54
JNKIN8 C29H29N7O2 507.59 JNK Zhang T. (2012) Chem Biol. 19(1) 140-54
KIN 112 C32H36N6O4 568.67 Lck Martin M.W. (2006) J.Med.Chem. 49 4981-4991
LRRK2-IN1 C31H38N8O3 570.69 LRRK2 Deng X. (2011) Nat. Chem. Biol. 7 203
Merck 7 (PDK1) C28H22F2N4O4 516.5 PDK1 Nagashima K. (2011) J.Biol.Chem. 286 6433-6448
MK-2206 C25H21N5O.2HCl 480.39 PKB Hui-Fang Li (2009) Radiation Oncology 4 43
MLi-2 C21H25N5O2 LRRK2 Matthew J. Fell (2015) Journal of Pharmacology and Experimental Therapeutics 355(3) 397-409
MLN120B C19H17Cl3N4O2 439.72 IKKb Nagashima K. Fraser C.C. (2006) Blood 107 4266-4273 Catley M.C. Newton R. (2006) Mol.Pharmacol. 70 697-705
MLN4924 C21H26ClN5O4S 479.98 NEDD8-activating enzyme Teresa A. Soucy (2009) Nature 458 732-736
MLN9708 C20H23BCl2N2O9 517.12 Proteasome Kupperman. E. (2010) Cancer Research 70 1970-1980

Pages

Do you need any help? Please get in touch and we’ll be happy to lend a hand.